Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Amarin Corporation plc AMRN

Healthcare Biotechnology
Amarin Corporation PLC is a pharmaceutical company. The Company is focused on the commercialization and development of therapeutics to improve cardiovascular (CV), health and reduce CV risk. The Company operates through the development and commercialization of VASCEPA. Its lead product, Vascepa (icosapent ethyl) capsule is used as an adjunct to diet to reduce triglyceride levels in adult... see more

Bullboard (NDAQ:AMRN)

View:
1 2 Next
Post by Tinekerensenon Apr 13, 2023 4:16am

Kevin Harrington Discusses FSD Pharma

I believe this new product will aid society in reducing the ...more  
87
Post by Tinekerensenon Apr 16, 2022 11:28am

FSD Pharma Inc: Lucid MS Video

FSD Pharma is delighted to announce pre-clinical findings ...more  
144
Post by Tinekerensenon Apr 09, 2022 1:00pm

FSD: Cancellation of Certain Shares Issued to Former CEO

FSD Pharma Announces Cancellation of Certain Shares Issued to Former Chief Executive Officer Dr. Raza Bokhari   TORONTO--(BUSINESS WIRE)--FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) ...more  
109
Post by Tinekerensenon Apr 07, 2022 12:50pm

FSD Pharma Issues Corporate Updates

FSD Pharma Issues Corporate Updates TORONTO--(BUSINESS WIRE)--FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) (“FSD Pharma” or the “Company”), a life sciences holding company dedicated to ...more  
84
Post by Tinekerensenon Apr 06, 2022 2:13am

iMining: First Hospital Foundation in Decentraland Metaverse

iMining Enters into Agreement for the First-Ever Hospital Foundation to Be Launched in the Decentraland Metaverse   Vancouver, British Columbia--(Newsfile Corp.) - iMining Technologies Inc ...more  
97
Post by Tinekerensenon Feb 04, 2022 11:19am

FSD Pharma Inc: Lucid MS Video

FSD Pharma is pleased to share pre-clinical data demonstrating the effectiveness of its lead drug candidate, Lucid-MS, in treating Multiple Sclerosis. The unique potential therapeutic value of Lucid ...more  
110
Post by Tinekerensenon Jan 01, 2022 1:22am

FSD Pharma Announces Share Repurchase Program

FSD Pharma Announces Share Repurchase Program   TORONTO--(BUSINESS WIRE)--FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) (“FSD Pharma” or the “Company”), a life sciences holding company ...more  
151
Post by Tinekerensenon Dec 10, 2021 9:57am

FSD Pharma Establishes New Regulatory Advisory Board

FSD Pharma Establishes New Regulatory Advisory Board with the Appointment of Joga Gobburu, Ph.D., and Mary Melnyk, Ph.D., as Members   Regulatory Advisory Board will oversee the drug development ...more  
123
1 2 Next
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Dealroom for high-potential pre-IPO opportunities